NCT00553735

The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye

The Prophylactic Use of Topical Cyclosporine A 0.05% (Restasis) to Prevent Onset and Progression of Graft-versus-host Disease-related Dry Eye

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Massachusetts Eye and Ear Infirmary · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether Restasis is an effective treatment for preventing the occurrence and progression of dry eye syndrome in patients who have recently received a bone marrow transplant and are at risk to graft-versus-host disease.

Detailed description

The purpose of this research study is to determine if early treatment using Restasis eye drops can prevent the development or delay the progression of dry eye syndrome in allogeneic bone marrow transplant (BMT) recipients.

Conditions

• Dry Eye

Interventions

Type	Name	Description
DRUG	Cyclosporine A 0.05%	Topical cyclosporine A 0.05% (Restasis) three times a day for 18 months.
DRUG	Arificial Tear	Artificial Tear - three times a day for 18 months.

Timeline

• Start date: 2007-08-01
• Primary completion: 2010-12-01
• Completion: 2010-12-01
• First posted: 2007-11-06
• Last updated: 2017-03-28
• Results posted: 2017-03-28

Locations

1 site across 1 country: United States